In non-small-cell lung cancer there are differences in transforming potential and EGFR tyrosine kinase inhibitor sensitivity associated with EGFR somatic mutations L858R and deletion mutant Del (746-750) (Carey et al, 2006). The gene discussed is EGFR; the disease is non-small cell lung carcinoma.